Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 53

1.

Primary Esophagogastric Neuroendocrine Carcinoma: a Retrospective Study from the Nottingham Upper Gastrointestinal Cancer Center.

Savva C, Kaye P, Soomro I, Parsons SL, James E, Madhusudan S.

J Gastrointest Cancer. 2018 Mar;49(1):85-92. doi: 10.1007/s12029-017-0039-2. No abstract available.

PMID:
29230683
2.

Development of a telehealth monitoring service after colorectal surgery: A feasibility study.

Bragg DD, Edis H, Clark S, Parsons SL, Perumpalath B, Lobo DN, Maxwell-Armstrong CA.

World J Gastrointest Surg. 2017 Sep 27;9(9):193-199. doi: 10.4240/wjgs.v9.i9.193.

3.

Multicentre cohort study to define and validate pathological assessment of response to neoadjuvant therapy in oesophagogastric adenocarcinoma.

Noble F, Lloyd MA, Turkington R, Griffiths E, O'Donovan M, O'Neill JR, Mercer S, Parsons SL, Fitzgerald RC, Underwood TJ; OCCAMS consortium.

Br J Surg. 2017 Dec;104(13):1816-1828. doi: 10.1002/bjs.10627. Epub 2017 Sep 25.

4.

The front-line general surgery consultant as a new model of emergency care.

Navarro AP, Hardy E, Oakley B, Mohamed E, Welch NT, Parsons SL.

Ann R Coll Surg Engl. 2017 Sep;99(7):550-554. doi: 10.1308/rcsann.2017.0081. Epub 2017 Jul 6.

PMID:
28682130
5.

Postoperative survival following perioperative MAGIC versus neoadjuvant OE02-type chemotherapy in oesophageal adenocarcinoma.

Reece-Smith AM, Saunders JH, Soomro IN, Bowman CR, Duffy JP, Kaye PV, Welch NT, Madhusudan S, Parsons SL.

Ann R Coll Surg Engl. 2017 May;99(5):378-384. doi: 10.1308/rcsann.2017.0024.

PMID:
28462649
6.

The role of adjuvant platinum-based chemotherapy in esophagogastric cancer patients who received neoadjuvant chemotherapy prior to definitive surgery.

Saunders JH, Bowman CR, Reece-Smith AM, Pang V, Dorrington MS, Mumtaz E, Soomro I, Kaye P, Madhusudan S, Parsons SL.

J Surg Oncol. 2017 Jun;115(7):821-829. doi: 10.1002/jso.24601. Epub 2017 Mar 2.

PMID:
28257148
7.

Individual patient oesophageal cancer 3D models for tailored treatment.

Saunders JH, Onion D, Collier P, Dorrington MS, Argent RH, Clarke PA, Reece-Smith AM, Parsons SL, Grabowska AM.

Oncotarget. 2017 Apr 11;8(15):24224-24236. doi: 10.18632/oncotarget.12500.

8.

The relationship of plantar cutaneous sensation and standing balance post-stroke.

Parsons SL, Mansfield A, Inness EL, Patterson KK.

Top Stroke Rehabil. 2016 Oct;23(5):326-32. doi: 10.1080/10749357.2016.1162396. Epub 2016 Mar 31.

PMID:
27077993
9.

3-Dimensional Patient-Derived Lung Cancer Assays Reveal Resistance to Standards-of-Care Promoted by Stromal Cells but Sensitivity to Histone Deacetylase Inhibitors.

Onion D, Argent RH, Reece-Smith AM, Craze ML, Pineda RG, Clarke PA, Ratan HL, Parsons SL, Lobo DN, Duffy JP, Atherton JC, McKenzie AJ, Kumari R, King P, Hall BM, Grabowska AM.

Mol Cancer Ther. 2016 Apr;15(4):753-63. doi: 10.1158/1535-7163.MCT-15-0598. Epub 2016 Feb 12.

10.

Sarcopenia is associated with toxicity in patients undergoing neo-adjuvant chemotherapy for oesophago-gastric cancer.

Tan BH, Brammer K, Randhawa N, Welch NT, Parsons SL, James EJ, Catton JA.

Eur J Surg Oncol. 2015 Mar;41(3):333-8. doi: 10.1016/j.ejso.2014.11.040. Epub 2014 Nov 26.

PMID:
25498359
11.

The role of relative lymphocyte count as a biomarker for the effect of catumaxomab on survival in malignant ascites patients: results from a phase II/III study.

Heiss MM, Ströhlein MA, Bokemeyer C, Arnold D, Parsons SL, Seimetz D, Lindhofer H, Schulze E, Hennig M.

Clin Cancer Res. 2014 Jun 15;20(12):3348-57. doi: 10.1158/1078-0432.CCR-13-2351. Epub 2014 Apr 8.

12.

Analysis of lymphatic and blood vessel invasion biomarkers in T1 esophagogastric adenocarcinomas for improved patient prognostication.

Perry C, Soomro I, Kaye P, Hardy E, Parsons SL, Ragunath K, Lobo DN, Martin SG, Madhusudan S.

Dis Esophagus. 2015 Apr;28(3):262-8. doi: 10.1111/dote.12190. Epub 2014 Feb 24.

PMID:
24612464
13.

British Society of Gastroenterology guidelines on the diagnosis and management of Barrett's oesophagus.

Fitzgerald RC, di Pietro M, Ragunath K, Ang Y, Kang JY, Watson P, Trudgill N, Patel P, Kaye PV, Sanders S, O'Donovan M, Bird-Lieberman E, Bhandari P, Jankowski JA, Attwood S, Parsons SL, Loft D, Lagergren J, Moayyedi P, Lyratzopoulos G, de Caestecker J; British Society of Gastroenterology.

Gut. 2014 Jan;63(1):7-42. doi: 10.1136/gutjnl-2013-305372. Epub 2013 Oct 28.

PMID:
24165758
14.

Thioredoxin interacting protein and its association with clinical outcome in gastro-oesophageal adenocarcinoma.

Woolston CM, Madhusudan S, Soomro IN, Lobo DN, Reece-Smith AM, Parsons SL, Martin SG.

Redox Biol. 2013 May 23;1:285-91. doi: 10.1016/j.redox.2013.04.006. eCollection 2013.

15.

Reduction in length of stay for patients undergoing oesophageal and gastric resections with implementation of enhanced recovery packages.

Tang J, Humes DJ, Gemmil E, Welch NT, Parsons SL, Catton JA.

Ann R Coll Surg Engl. 2013 Jul;95(5):323-8. doi: 10.1308/003588413X13629960046039.

16.

Venous thromboembolism in patients receiving perioperative chemotherapy for esophagogastric cancer.

Khanna A, Reece-Smith AM, Cunnell M, Madhusudan S, Thomas A, Bowrey DJ, Parsons SL.

Dis Esophagus. 2014 Apr;27(3):242-7. doi: 10.1111/dote.12084. Epub 2013 May 7.

PMID:
23651074
17.

Expression of the calpain system is associated with poor clinical outcome in gastro-oesophageal adenocarcinomas.

Storr SJ, Pu X, Davis J, Lobo D, Reece-Smith AM, Parsons SL, Madhusudan S, Martin SG.

J Gastroenterol. 2013 Nov;48(11):1213-21. doi: 10.1007/s00535-012-0743-4. Epub 2013 Jan 19.

PMID:
23329366
18.

Are DNA repair factors promising biomarkers for personalized therapy in gastric cancer?

Abdel-Fatah T, Arora A, Gorguc I, Abbotts R, Beebeejaun S, Storr S, Mohan V, Hawkes C, Soomro I, Lobo DN, Parsons SL, Madhusudan S.

Antioxid Redox Signal. 2013 Jun 20;18(18):2392-8. doi: 10.1089/ars.2012.4873. Epub 2012 Oct 19.

PMID:
22894650
19.

Deterioration in quality of life (QoL) in patients with malignant ascites: results from a phase II/III study comparing paracentesis plus catumaxomab with paracentesis alone.

Wimberger P, Gilet H, Gonschior AK, Heiss MM, Moehler M, Oskay-Oezcelik G, Al-Batran SE, Schmalfeldt B, Schmittel A, Schulze E, Parsons SL.

Ann Oncol. 2012 Aug;23(8):1979-85. doi: 10.1093/annonc/mds178. Epub 2012 Jun 24.

20.

MAGIC in practice: experience of peri-operative ECF/X chemotherapy in gastro-esophageal adenocarcinomas.

Reece-Smith AM, Saha S, Cunnell ML, Hameed K, Bessell EM, Duffy JP, Madhusudan S, Parsons SL.

J Surg Oncol. 2012 Nov;106(6):748-52. doi: 10.1002/jso.23187. Epub 2012 Jun 4.

PMID:
22674046

Supplemental Content

Loading ...
Support Center